Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Stoeckle

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
AIDS (London, England)|January 18, 2023
Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort studyFanny Blondet, Vanessa Kraege, Matthias Cavassini, et al.
Open Forum Infectious Diseases|August 4, 2025
Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study DataSoheila Aghlmandi, Kurt Schmidlin, Carola Huber, et al.
Open Forum Infectious Diseases|November 7, 2024
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV TrialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Open Forum Infectious Diseases|August 11, 2023
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19Catrina Mugglin, Kalongo Hamusonde, Luisa Salazar-Vizcaya, et al.
Journal of the International AIDS Society|November 14, 2014
Loss to follow-up of HIV-infected women after delivery: The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort StudyKaroline Aebi-Popp, Roger Kouyos, Barbara Bertisch, et al.
Open Forum Infectious Diseases|September 19, 2024
Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular RiskIrene A Abela, Frédérique Chammartin, Alain Amstutz, et al.
Swiss Medical Weekly|May 16, 2024
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Plos Medicine|November 10, 2020
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialDelphine Sculier, Gilles Wandeler, Sabine Yerly, et al.
BMC Infectious Diseases|March 20, 2024
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocolMaxime Hentzien, Fabrice Bonnet, Enos Bernasconi, et al.
British Journal of Clinical Pharmacology|March 25, 2021
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trialPerrine Courlet, Charlotte Barbieux, Delphine Sculier, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|January 18, 2023
Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort studyFanny Blondet, Vanessa Kraege, Matthias Cavassini, et al.
Open Forum Infectious Diseases|August 4, 2025
Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study DataSoheila Aghlmandi, Kurt Schmidlin, Carola Huber, et al.
Open Forum Infectious Diseases|November 7, 2024
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV TrialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Open Forum Infectious Diseases|August 11, 2023
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19Catrina Mugglin, Kalongo Hamusonde, Luisa Salazar-Vizcaya, et al.
Journal of the International AIDS Society|November 14, 2014
Loss to follow-up of HIV-infected women after delivery: The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort StudyKaroline Aebi-Popp, Roger Kouyos, Barbara Bertisch, et al.
Open Forum Infectious Diseases|September 19, 2024
Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular RiskIrene A Abela, Frédérique Chammartin, Alain Amstutz, et al.
Swiss Medical Weekly|May 16, 2024
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Plos Medicine|November 10, 2020
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialDelphine Sculier, Gilles Wandeler, Sabine Yerly, et al.
BMC Infectious Diseases|March 20, 2024
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocolMaxime Hentzien, Fabrice Bonnet, Enos Bernasconi, et al.
British Journal of Clinical Pharmacology|March 25, 2021
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trialPerrine Courlet, Charlotte Barbieux, Delphine Sculier, et al.
Pageof 8